Proteins and Peptides
13 February 2018
Bicycle Therapeutics and Cancer Research UK Announce Initiation of First Clinical Study of a Bicyclic Peptide (Bicycle®)13 February 2018
Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis13 February 2018
Ra Pharmaceuticals Announces Completion of Dosing in Phase 2 Program of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria9 February 2018
Novo Nordisk A/S: Ozempic® (semaglutide) approved in the EU for the treatment of type 2 diabetes8 February 2018
Bonti Announces Dosing of the First Patient in the SHINE-1 Phase 2 Clinical Study Evaluating EB-001 for Scar Reduction8 February 2018
BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at WORLDSymposium™ 20188 February 2018
Sanofi announces new safety data for investigational avalglucosidase alfa in patients with Pompe disease7 February 2018
Symic Bio Completes the MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Knee Osteoarthritis6 February 2018
Endo Announces Initiation Of Two Pivotal Phase 3 Clinical Trials Of Collagenase Clostridium Histolyticum For The Treatment Of Cellulite6 February 2018
Spectrum Pharmaceuticals Announces ROLONTIS™ (eflapegrastim) Met the Primary Endpoint in the Phase 3 ADVANCE Study1 February 2018
Ferring’s ZOMACTON® (somatropin) for Injection Receives FDA Approval to Treat Growth Hormone Deficiency in Adults1 February 2018
Partner Therapeutics (PTx) Acquires Leukine® from Sanofi30 January 2018
Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS® (carfilzomib) Label29 January 2018
Mylan and Biocon Receive Positive CHMP Opinion for Semglee™, Biosimilar Insulin Glargine27 January 2018
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors25 January 2018
Generon Successfully Concludes First Phase III Clinical Trial of F-627 for Chemotherapy-Induced Neutropenia24 January 2018
Biomarck Announces the Start of a Phase 2 Clinical Trial of BIO-11006 for Non-Small Cell Lung Cancer (NSCLC)23 January 2018
FDA accepts investigational new drug application and grants Fast Track status for SOBI003 for the treatment of MPS IIIA23 January 2018
New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome (SBS)22 January 2018
Baxter Announces U.S. FDA Approval of Ready-to-Use Cardiovascular Medication Bivalirudin22 January 2018
Octapharma: Low inhibitor rate with octanate® in previously untreated patients (PUPs) with severe haemophilia ANews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports